Simon Burton

Without treatment 1 in 10 people with latent TB will progress to active TB but how can they be identified?

PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations

The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.

The 2023 AACC Annual Scientific Meeting & Clinical Lab Expo will be an opportunity to find out more about phage-based diagnostics.

Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB.

The Microbiology Society Annual Conference 2023 will take place 17 -20 April 2023 at Birmingham International Convention Centre.

We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.

The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted by the AACC, it has been announced ahead of World TB Day.

With advances in diagnostics, can we now begin to practice preventative medicine rather than treating the symptoms?

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.